for educational and safety purposes
Every compound in the sci-wiki that affects neuroprotection; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
9 sourced · 18 reference
EPObis is a synthetic dendrimeric peptide designed from the binding Site 1 sequence of human erythropoietin, guided by the crystal structure of the erythropoietin-receptor complex. It binds the erythropoietin receptor and reproduces the cytokine's tissue-protective signaling; in cultured neurons it promotes neurite outgrowth and survival in a receptor-dependent manner. Unlike erythropoietin itself, EPObis is non-erythropoietic, so it activates protective pathways without stimulating red blood cell production, and after systemic administration it crosses the blood-brain barrier into the cerebrospinal fluid. In rodent studies it reduces tumor necrosis factor release from activated macrophages and microglia, delays clinical signs in experimental autoimmune encephalomyelitis, and enhances working memory, marking it as an experimental neuroprotective and anti-inflammatory research peptide.
N-PEP-12 is an oral dietary supplement of small brain-derived peptides and free amino acids, sold as Memoprove and described by its own investigators as a lower-potency, needle-free relative of the injectable neurotrophic drug Cerebrolysin. Small, mostly manufacturer-linked studies report modest short-term gains in memory and brain EEG activity in aging adults and in stroke recovery. It is an appealing, gentle nootropic idea, but the human evidence is thin and largely industry-linked, and the core assumption that oral brain peptides survive digestion to reach the brain remains pharmacologically unproven.
Taltirelin (TA-0910, brand name Ceredist) is a synthetic, metabolically stable analog of thyrotropin-releasing hormone (TRH), the three-residue hypothalamic peptide. It was developed by Tanabe Seiyaku and approved in Japan in 2000 for spinocerebellar degeneration, where it is taken orally to help with ataxia and related symptoms. The interesting thing about taltirelin is that it was engineered to keep the central nervous system effects of TRH while shedding most of the hormonal ones; it is roughly 10 to 100 times more potent than native TRH at driving CNS arousal, yet its effect on thyroid hormone release is much weaker. It also lasts far longer in the body because it resists the enzymes that chew up natural TRH within minutes. Outside its approved use it gets discussed in nootropic and biohacker circles as a wakefulness-promoting, pro-cholinergic "analeptic" and neuroprotective agent, and there is a real preclinical literature behind those claims (Parkinson's models, ischemia, pain, respiratory stimulation). Human data outside spinocerebellar degeneration is thin, so most of what you read about it as a cognitive enhancer is extrapolation from animal work.
7,8-Dihydroxyflavone (7,8-DHF), also called tropoflavin, is a naturally occurring flavone studied as a small-molecule mimic of brain-derived neurotrophic factor (BDNF). It is reported to act as an agonist of tropomyosin receptor kinase B (TrkB), the principal BDNF receptor, binding the receptor's extracellular domain to drive its dimerization and activation, and because it is orally active and crosses the blood-brain barrier it has become a widely used tool compound in neuroscience. Its direct activation of TrkB is not fully settled, however, since some quantitative assays have been unable to reproduce it, and it remains an experimental compound studied in models of depression, Alzheimer's, and other neurological conditions.
Dehydroepiandrosterone (DHEA) is an endogenous androstane neurosteroid and the most abundant circulating steroid hormone in humans, secreted chiefly by the adrenal cortex and also synthesized de novo within the central nervous system. It functions primarily as a precursor to androgens and estrogens, yet exerts direct actions on the brain by acting as an agonist at the sigma-1 receptor (an endoplasmic reticulum chaperone protein that shapes calcium and neurotrophic signaling), as a positive modulator of NMDA receptor (the principal excitatory glutamate ion channel involved in learning) signaling, and, chiefly as its sulfate ester DHEAS, as a negative allosteric modulator of the GABA-A receptor (the brain's main inhibitory ion channel). DHEA additionally behaves as a functional anti-glucocorticoid, buffering the neurotoxic effects of cortisol, and shows neuroprotective and mood-related activity in preclinical and clinical studies. Circulating concentrations peak in early adulthood and decline markedly with age, a phenomenon termed adrenopause that has driven its widespread use as an over-the-counter supplement.
Indolepropionamide (IPAM) is a naturally occurring indole compound, chemically related to melatonin, that has been studied as a mitochondrial protectant and antioxidant. In laboratory research it was reported to stabilize energy production in mitochondria, lower the output of reactive oxygen species, and extend lifespan in a simple invertebrate model. It remains an investigational substance with limited study rather than an approved medicine.
Lithium orotate is a salt of lithium and orotic acid sold as a low-dose dietary supplement. It provides much less elemental lithium per tablet than the lithium carbonate used as a prescription mood stabilizer, and it is marketed for mood and general wellbeing. It is not approved as a medicine, and rigorous human evidence for its benefits is lacking.
Rosemary extract is a concentrated preparation of the culinary herb Rosmarinus officinalis (now often classed as Salvia rosmarinus). Its active fraction is dominated by two polyphenols; carnosic acid, a fat-soluble diterpene that activates the body's own antioxidant defenses, and rosmarinic acid, a water-soluble caffeic acid ester. The plant's volatile oil also carries 1,8-cineole, the aromatic component tied to rosemary's cognitive reputation. It's studied mostly for memory support, antioxidant activity, and mild mood effects.
Progesterone (P4; pregn-4-ene-3,20-dione) is an endogenous pregnane steroid hormone best known for its reproductive roles and is the prototypical neuroactive precursor within the neurosteroid system. Although the parent hormone signals principally through classical nuclear progesterone receptors and through membrane-associated receptors such as PGRMC1 and the mPR/PAQR family, most of its rapid effects on neuronal excitability arise only after sequential metabolism to 5-alpha-dihydroprogesterone and then to allopregnanolone, one of the most potent endogenous positive allosteric modulators of the GABA-A receptor (the brain's principal inhibitory chloride channel). Progesterone and its metabolites are synthesized within the nervous system itself, where they regulate myelination, neuronal survival, neuroinflammation, and inhibitory tone. It has been studied extensively as a neuroprotective agent, with strong preclinical support but negative large-scale human trials in acute traumatic brain injury.
24(S)-Hydroxycholesterol (historically named cerebrosterol) is an endogenous oxysterol (an oxygenated derivative of cholesterol) generated almost exclusively in neurons by the enzyme cholesterol 24-hydroxylase (CYP46A1). It is the principal chemical route by which the brain, which cannot degrade cholesterol, exports its surplus; because the added hydroxyl group at carbon 24 allows the molecule to cross the blood-brain barrier (the selective interface between blood and brain tissue), plasma levels of 24(S)-hydroxycholesterol serve as an accessible marker of brain cholesterol turnover and neuronal mass. Beyond its housekeeping role, it is a bona fide neurosteroid; at physiological concentrations it acts as a potent positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors (a class of glutamate-gated ion channels central to learning and memory) and as an agonist of liver X receptors (LXR, nuclear receptors that govern lipid handling). Its pharmacology inspired the synthetic analog dalzanemdor (SAGE-718), an NMDA receptor positive allosteric modulator developed for cognitive impairment.
Androstenediol (androst-5-ene-3β,17β-diol, commonly abbreviated 5-androstenediol or 5-AED) is an endogenous Δ5 androstane steroid formed as a direct metabolite of dehydroepiandrosterone (DHEA, the most abundant circulating adrenal steroid). It sits at a branch point in steroidogenesis, functioning both as a weak, ERβ-preferring estrogen (a steroid that activates the estrogen receptor) and as a prohormone that can be converted onward to testosterone. Its most distinctive documented activity is immunomodulatory and hematopoietic; under the development code Neumune it was investigated as a radiation countermeasure that accelerates recovery of white blood cells and platelets after whole-body irradiation. Its inclusion in the neurosteroid grouping is one of exhaustiveness, since unlike allopregnanolone it has only a marginal classic neurosteroid profile at the GABA-A and NMDA receptors, and its central effects are attributed mainly to estrogen receptor beta signaling.
Colivelin is a synthetic 26-amino-acid hybrid peptide built by fusing a short activity-dependent neurotrophic factor fragment (ADNF-9, SALLRSIPA) to the N-terminus of a potent humanin derivative, AGA-(C8R)HNG17. It was engineered to protect neurons from the kinds of insults tied to Alzheimer's disease and other neurodegeneration, and it does so in cell models at femtomolar concentrations, far below its parent peptides. Researchers look at it mainly as a neuroprotective tool compound rather than an approved drug.
Davunetide (NAP; NAPVSIPQ) is an eight-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP) that stabilizes microtubules and reduces tau pathology, and has been evaluated clinically as an intranasal neuroprotective agent [1][2]. Although early studies suggested cognitive benefit in amnestic mild cognitive impairment and functional improvement in schizophrenia, a large phase 2/3 trial in progressive supranuclear palsy (PSP) found no clinical efficacy [1][3].
DHEA sulfate (DHEAS) is the 3-beta sulfate ester of dehydroepiandrosterone and the most abundant circulating steroid in the human body, present in plasma at concentrations roughly a thousandfold higher than unconjugated DHEA. Synthesized principally in the zona reticularis of the adrenal cortex, it functions as a stable, long-lived reservoir that is interconverted with DHEA and supplies a precursor pool for downstream androgens and estrogens. Within the nervous system it is classified as a neurosteroid (a steroid synthesized in or acting directly upon nervous tissue); it acts as an agonist at the sigma-1 receptor (an intracellular chaperone protein), a positive modulator of the NMDA receptor (a glutamate-gated excitatory ion channel), and a negative allosteric modulator of the GABA-A receptor (the brain's principal inhibitory ion channel), giving it a net excitatory, pro-cognitive neuromodulatory profile. Circulating concentrations fall markedly with age, a decline termed adrenopause that has made DHEAS a widely studied biomarker of adrenal function, cognitive aging, and longevity.
Etazolate (EHT-0202) is a fascinating triple-mechanism molecule: a 1970s pyrazolopyridine anxiolytic that ExonHit repurposed for Alzheimer's disease. In one compound it combines PDE4 inhibition, positive allosteric modulation of GABA-A receptors, and stimulation of alpha-secretase, which raises the neurotrophic, neuroprotective fragment sAPPalpha and steers amyloid precursor protein away from toxic amyloid. It is one of the few compounds in this class to have actually completed a placebo-controlled Phase 2 trial in Alzheimer's patients.
Ethomersol is a benzimidazole actoprotector and antihypoxant (5-ethoxy-2-ethylthio-1H-benzimidazole) developed within the Soviet military-medical pharmacology school as the lipophilic 5-ethoxy analog of bemitil. As an actoprotector it is designed to raise and sustain physical and mental work capacity under adverse conditions without increasing oxygen consumption or heat production, placing it in the same "synthetic adaptogen" class as bemitil and bromantane. It belongs to the aliphatic and cyclic aminothiol lineage synthesized by F.Yu. Rachinsky and studied under V.M. Vinogradov at the S.M. Kirov Military Medical Academy, alongside gutimin, amtizole and bemitil. Rather than acting on a classical receptor, it normalizes cellular energy metabolism during oxygen deficit, acts as a direct antioxidant, and stimulates adaptive protein synthesis, giving it combined antihypoxic, antioxidant, energotropic and reparative activity documented in preclinical models of hypoxia, toxic injury, and traumatic brain injury.
HNG is a synthetic potency-boosted analog of humanin, a 24-amino-acid peptide encoded within mitochondrial DNA. Swapping one residue (serine to glycine at position 14) makes it roughly a thousand times more cytoprotective than natural humanin in cell assays, which is why almost all animal work on the humanin pathway uses HNG rather than the wild-type peptide. It is studied for protecting neurons against amyloid-beta and ischemic insults, and for metabolic and insulin-sensitizing effects.
Homotaurine, chemically 3-amino-1-propanesulfonic acid (3APS), is a small aminosulfonic acid that occurs naturally in certain marine red algae; it is a homolog of the amino acid taurine and a structural analog of the inhibitory neurotransmitter GABA, and it behaves as a GABA-A receptor modulator. Its pharmaceutical interest, however, comes from a different property: it is an anti-amyloid agent that binds soluble amyloid-beta and inhibits its aggregation into neurotoxic oligomers. Under the drug name tramiprosate it was carried into large phase 3 Alzheimer's disease trials that were negative overall, yet a subgroup signal tied to the APOE4 genotype survived the failure and drove a second act. That signal spawned a valine-conjugated prodrug, ALZ-801 (valiltramiprosate), now studied specifically in APOE4/4 homozygotes with early Alzheimer's disease. Homotaurine is also sold as a nutraceutical for memory, where its efficacy remains unproven.
LM22A-4 is a rationally designed small-molecule mimetic of the loop-II domain of BDNF that activates the TrkB neurotrophin receptor, discovered by in-silico screening in the Longo and Massa labs. It is a foundational research tool for the BDNF/TrkB arm of the neuroplasticity pathway, with broad neuroprotective, remyelinating, and cognition-rescuing activity across rodent models; offering a drug-like way to probe signaling normally driven by a large neurotrophin.
MIF-1 (Pro-Leu-Gly-NH2), also called melanostatin, is a small endogenous tripeptide made in the body. It was first recognized as the hypothalamic factor that inhibits release of melanocyte-stimulating hormone from the pituitary, and it was later found to act in the brain as a positive allosteric modulator of dopamine D2 receptors. Because of that dopamine-enhancing action it has been studied as a potential treatment for depression and Parkinson's disease.
PRE-084 is a synthetic, highly selective agonist of the sigma-1 receptor, an endoplasmic reticulum chaperone protein that modulates calcium signaling, neurotrophic factor expression, and cellular stress responses. It is used almost exclusively as a preclinical research tool, where it has produced neurorestorative effects in models of Parkinson disease [1], motor neuron survival in models of amyotrophic lateral sclerosis [2], and antidepressant and anti-amnesic activity [5]. A recurring theme across studies is upregulation of brain-derived neurotrophic factor (BDNF) and downstream trophic pathways [2][3][4].
Rapastinel (originally GLYX-13) is a tiny four-amino-acid peptide (Thr-Pro-Pro-Thr with an amidated tail) that acts as a functional partial agonist at the glycine site of the NMDA receptor. It was the lead candidate in the wave of rapid-acting antidepressants inspired by ketamine, meant to lift mood within a day without ketamine's dissociation; it looked promising through phase 2 but failed its phase 3 depression trials in 2019.
Tetrahydrocannabinolic acid (THCA) is the non-intoxicating acidic cannabinoid that predominates in living and freshly harvested Cannabis sativa, where it can account for the large majority of the plant's total THC content [2]. It is the direct biosynthetic precursor of Δ9-tetrahydrocannabinol (THC): heating, aging, smoking, or vaporizing drives a decarboxylation reaction that strips off a carboxyl group and converts THCA into psychoactive THC, which is why raw, unheated cannabis does not produce a high [2][8]. Unlike THC, THCA binds the CB1 receptor only weakly, yet it is a comparatively potent agonist of the nuclear receptor PPAR-gamma and shows anti-inflammatory, neuroprotective, and anti-emetic activity in preclinical models [1][3][4]. Human evidence remains limited, and much of the interest in THCA centers on raw-cannabis juicing and non-heated preparations [7].
VD11 is an 11-amino-acid linear peptide (VDELWPPWLPC) isolated from the spinal cord of the Chinese odorous frog Odorrana schmackeri. In one preclinical study it pushed microglia to release the neurotrophic factors NGF and BDNF and helped rats recover motor function after a complete spinal cord transection. People look at it as an early-stage, frog-derived candidate for central nervous system repair, not as a supplement.
Fingolimod is a sphingosine-1-phosphate receptor modulator used to treat relapsing forms of multiple sclerosis. Approved in 2010 and sold as Gilenya, it was the first oral disease-modifying therapy for the condition, offering an alternative to injections for many patients. It works by trapping immune cells in the lymph nodes so that fewer of them can reach and attack the brain and spinal cord.
Neotrofin is the brand name for leteprinim potassium (development code AIT-082), a small purine derivative of hypoxanthine that was investigated as a neurotrophic and memory-enhancing agent. Developed by the company NeoTherapeutics, it works indirectly by prompting the brain to make more of its own neurotrophic factors, such as nerve growth factor. It was tested in Alzheimer's disease but the program was discontinued after only modest results, and it never reached approval.
DHED (10-beta,17-beta-dihydroxyestra-1,4-dien-3-one) is an experimental bioprecursor prodrug of the estrogen 17-beta-estradiol that is inert at estrogen receptors until it is converted to the active hormone. Its defining feature is a striking tissue selectivity: a reductase reaction that occurs in nervous tissue regenerates estradiol within the brain and retina after systemic or topical dosing, while the molecule remains unchanged in the periphery, so it does not raise circulating estrogen or stimulate the uterus, breast, or pituitary. In rodent models this brain-restricted delivery has relieved menopausal and androgen-deprivation hot flushes, provided neuroprotection after stroke, and, as eye drops, preserved retinal ganglion cells and visual function in glaucoma models. DHED remains a preclinical agent, but it exemplifies a prodrug strategy aimed at capturing estrogen's central benefits while avoiding the systemic risks that limit conventional hormone therapy.